Cargando…

Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report

Myocardial metastasis of nasopharyngeal carcinoma (NPC) is rarely reported in the literature. Some autopsy studies found metastases in more than 10% of cases with malignant neoplasm. However, patients are often diagnosed during the postmortem because myocardial metastasis is often asymptomatic, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Xiaowan, Zhou, Weijun, Huang, Danjiang, Chen, Lili, Zhang, Guangwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602087/ https://www.ncbi.nlm.nih.gov/pubmed/34804001 http://dx.doi.org/10.3389/fimmu.2021.688682

Ejemplares similares

Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma
por: Kong, Xiangyi, et al.
Publicado: (2022)

Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma
por: Huang, Huimei, et al.
Publicado: (2021)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti–PD–1 antibody
por: Xu, Bin, et al.
Publicado: (2022)

Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma
por: Ali, Wael A. S., et al.
Publicado: (2023)

Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma
por: Zhou, Na, et al.
Publicado: (2022)

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody
por: Liu, Chenxi, et al.
Publicado: (2022)

Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy
por: Lin, Mao, et al.
Publicado: (2022)

Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?
por: Zhou, Xin, et al.
Publicado: (2021)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
por: Que, Yi, et al.
Publicado: (2021)

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
por: Bai, Rilan, et al.
Publicado: (2022)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022)

Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy
por: Lin, Xinqing, et al.
Publicado: (2021)

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
por: Yang, Zhengyang, et al.
Publicado: (2022)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor
por: Liu, Guo-Ying, et al.
Publicado: (2023)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response
por: Chen, Zi-Hang, et al.
Publicado: (2023)

Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors
por: Benguigui, Madeleine, et al.
Publicado: (2022)

Editorial: Stromal and immune microenvironment in breast cancer metastasis
por: Lu, Xin, et al.
Publicado: (2022)

Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma
por: Li, Wenting, et al.
Publicado: (2023)

Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma
por: Tang, Siqi, et al.
Publicado: (2023)

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
por: Akbar, Shayista, et al.
Publicado: (2023)

Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
por: Li, Bin, et al.
Publicado: (2020)

PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study
por: Su, Ke, et al.
Publicado: (2022)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma
por: Secondino, Simona, et al.
Publicado: (2023)

Vitamin D metabolism pathway polymorphisms are associated with efficacy and safety in patients under anti-PD-1 inhibitor therapy
por: Luo, Jianquan, et al.
Publicado: (2022)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
por: Yin, Jianqiong, et al.
Publicado: (2022)

Nasopharyngeal carcinoma metastasis to the breast
por: Albasri, Abdulkader M.
Publicado: (2020)

The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma
por: Zeng, Hui, et al.
Publicado: (2023)

Characteristics of immunotherapy trials for nasopharyngeal carcinoma over a 15-year period
por: Huang, Huageng, et al.
Publicado: (2023)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023)

CFTR is a potential marker for nasopharyngeal carcinoma prognosis and metastasis
por: Tu, Ziwei, et al.
Publicado: (2016)

Advanced Cell Therapies for Glioblastoma
por: Wang, Guangwen, et al.
Publicado: (2022)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

Predictive and prognostic role of early apolipoprotein A‐I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti‐PD‐1 therapy
por: Xiao, Bi Jing, et al.
Publicado: (2023)

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
por: Zhou, Li, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_811pce7r2la5ktso1do526o2qv